B
BPMC

Bailard’s Blueprint Medicines BPMC Stock Holding History

Bailard’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35,867
Closed -$1.81M – 676
2022
Q2 		$1.81M Sell
35,867
-45,577
-56% -$2.67M 0.07% 193
2022
Q1 		$5.2M Sell
81,444
-16,472
-17% -$1.18M 0.18% 114
2021
Q4 		$10.5M Sell
97,916
-1,023
-1% -$107K 0.33% 71
2021
Q3 		$10.2M Buy
98,939
+14,294
+17% +$1.33M 0.35% 65
2021
Q2 		$7.45M Buy
84,645
+77,645
+1,109% +$7.11M 0.26% 91
2021
Q1 		$681K Buy
+7,000
New +$699K 0.03% 316

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bailard's BPMC Position: Q3 2022 in Review

Bailard sold out of Blueprint Medicines (BPMC) in Q3 2022, closing a stake of 35,867 shares — an estimated $1.81M sold.

Bailard first reported a position in BPMC in Q1 2021 and held it in 6 quarters. The position peaked at $10.5M in Q4 2021. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

  • Bailard reported no remaining Blueprint Medicines position as of Q3 2022 after selling out during the quarter.
  • Bailard sold 35,867 Blueprint Medicines shares in Q3 2022, an estimated $1.81M.
  • Bailard first reported a position in Blueprint Medicines in Q1 2021 and held it in 6 quarters.
  • Bailard's Blueprint Medicines position peaked at $10.5M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.